RT Journal Article
SR Electronic
T1 Development of a core measurement set for research in degenerative cervical myelopathy: a study protocol (AO Spine RECODE-DCM CMS)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.11.21266170
DO 10.1101/2021.11.11.21266170
A1 Davies, Benjamin M.
A1 Touzet, Alvaro Yanez
A1 Mowforth, Oliver D.
A1 Lee, Keng Siang
A1 Khan, Danyal
A1 Furlan, Julio C.
A1 Fehlings, Michael G.
A1 Harrop, James
A1 Zipser, Carl M.
A1 Rodrigues-Pinto, Ricardo
A1 Milligan, James
A1 Sarewitz, Ellen
A1 Curt, Armin
A1 Rahimi-Movaghar, Vafa
A1 Aarabi, Bizhan
A1 Boerger, Timothy F.
A1 Tetreault, Lindsay
A1 Chen, Robert
A1 Guest, James D.
A1 Kalsi-Ryan, Sukhvinder
A1 Sadler, Iwan
A1 Widdop, Shirley
A1 McNair, Angus G. K.
A1 Kotter, Mark R. N.
A1 On behalf of the AO Spine RECODE-DCM Steering Committee
YR 2021
UL http://medrxiv.org/content/early/2021/11/12/2021.11.11.21266170.abstract
AB Introduction Progress in degenerative cervical myelopathy (DCM) is hindered by inconsistent measurement and reporting of outcomes. This can, for example, impede the aggregation of data and comparison of outcomes between studies. This limitation can be reversed by developing a core measurement set (CMS) for use in DCM research. Previously, the AO Spine Research Objectives and Common Data Elements for DCM (AO Spine RECODE-DCM) defined ‘what’ should be measured in DCM: specifically, the core data elements and core outcome set of the disease. The next step of this initiative is to determine ‘how’ to measure these features. The current protocol outlines the steps necessary for the development of a CMS for DCM research and audit.Methods and analysis The CMS will be developed in accordance with the guidance developed by the Core Outcome Measures in Effectiveness Trials (COMET) and the Consensus-based Standards for the selection of health Measurement Instruments (COSMIN). The process will involve five phases: (1) agreement on the measurement constructs and approaches to their evaluation; (2) the formation of a long list of potential measurement instruments, by identifying existing instruments and assessing their psychometric properties; (3) the aggregation of evidence concerning ‘when’ measurements should be taken; (4) consensus about which instruments to include in the CMS; and (5) implementation.Ethics and dissemination Ethical approval was obtained from the University of Cambridge. Dissemination strategies to promote awareness and adoption of the CMS include peer-reviewed scientific publications; conference presentations; podcasts; the identification of AO Spine RECODE-DCM ambassadors; and engagement with relevant journals, funders, and the DCM community.Impact of this work The proposed project will enable standardised and comprehensive measurement in DCM clinical trials. The CMS will be established using a robust, global, and multi-stakeholder consensus process, with broad representation of healthcare professionals and individuals living with the disease. It will focus on measurement instruments currently in use. This ensures that the CMS will be immediately usable and suited for widespread adoption. The development of better outcome instruments in DCM remains a top 10 research priority and this work will hence facilitate knowledge generation for this important disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by AO Spine through the AO Spine Knowledge Forum Spinal Cord Injury, a focused group of international Spinal Cord Injury experts. AO Spine is a clinical division of the AO Foundation, which is an independent, medically guided not-for-profit organisation. Study support was provided directly through the AO Spine Research Department.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this project was obtained from the University of Cambridge (Ethical approval number: HBREC2019.14).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.